(WHS-P12) INTRAVENOUS FIBONECTIN (FN)-DERIVED cnp8 PEPTIDE PHASE 1 STUDY
Friday, May 2, 2025
7:45 PM – 8:45 PM East Coast USA Time
R.A. Clark, NeoMatrix Therapeutics, East Setauket, New York, UNITED STATES|S. Szambelan, Clinical Research, NeoMatrix Therapeutics, Inc., Stony Brook, New York, UNITED STATES|